Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2024-12-12 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
N4 101 In Vitro Results
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 7672P' and contains a date stamp '12 December 2024'. It provides an update on pre-clinical development results ('N4 101 in vitro Results') and includes commentary from the CEO, technical methodology, and contact information for brokers and the company. The presence of the RNS header and the nature of the content (a progress update/announcement) strongly suggest this is a regulatory disclosure disseminated via the London Stock Exchange's RNS system. Since it is an announcement detailing scientific progress and not a full annual report (10-K), interim report (IR), or a formal earnings release (ER), the most appropriate classification is the general regulatory announcement category, RNS.
2024-12-12 English
New Patent Filing
Report Publication Announcement Classification · 1% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange, which is approved by the FCA as a Primary Information Provider. The content announces a 'New Patent Filing' related to the company's product development, which is a specific corporate event announcement. Since this is a general regulatory announcement that doesn't fit into specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS.
2024-12-04 English
Grant of Options
Director's Dealing Classification · 1% confidence The document is identified by the RNS Number header and explicitly mentions being provided by RNS, the news service of the London Stock Exchange, which is approved by the FCA. The content details the 'Grant of Options' to directors and includes mandatory FCA notifications regarding transactions by persons discharging managerial responsibilities (PDMRs). This type of mandatory disclosure regarding insider transactions (director share dealings/option grants) is typically classified under Director's Dealing (DIRS) or sometimes as a general Regulatory Filing (RNS). Since there is a specific category for 'Director's Dealing' (DIRS) which covers 'Report of personal share transactions by company directors and executives (insider trades)', this is the most precise classification for the core content, even though it is distributed via RNS.
2024-11-28 English
N4 Pharma CEO Q&A Now LIVE
Regulatory Filings Classification · 1% confidence The document is a short announcement (3430 characters) released via RNS (RNS Number : 4862K) on November 1, 2024. The title is "N4 Pharma CEO Q&A Now LIVE". It explicitly states that an investor Q&A session with the CEO is being released and provides a link to the interactive investor hub where the response is live. This fits the definition of an announcement regarding the release or publication of specific investor content, rather than the content itself (like a CT or IP). Since it is a specific announcement about investor relations content being made available, it aligns best with Report Publication Announcement (RPA), which covers announcements about the release of company reports/information. While RNS is a fallback, RPA is more specific for announcements stating content is 'now LIVE' or 'published'.
2024-11-01 English
New Corporate Presentation
Regulatory Filings Classification · 1% confidence The document is a short announcement (4047 characters) released via RNS (RNS Number: 3814J) on October 24, 2024. The title is "New Corporate Presentation and CEO Q&A". The text explicitly states that the company is "pleased to announce the publication of a new corporate presentation accompanied by a video update from CEO, Nigel Theobald." It then provides links where the 'full slide deck is available to view'. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of another document (like a presentation), it should be classified as a Report Publication Announcement (RPA). It is not the presentation itself (IP) or a general regulatory filing (RNS), but specifically an announcement about the release of investor materials.
2024-10-24 English
Interim Results
Earnings Release Classification · 1% confidence The document explicitly states it announces the "unaudited interim results for the six months ended 30 June 2024." It contains detailed financial highlights (loss for the period, cash position) and an operational update covering scientific progress, which are characteristic features of a comprehensive interim financial report. The period covered is six months, which points towards an Interim/Quarterly Report (IR) rather than a full Annual Report (10-K). It is not merely an announcement of a report (RPA) because the full results and commentary are provided within the text, despite the document being filed via RNS (Regulatory Information Service). H1 2024
2024-09-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.